SCHEMBL6288955

SCHEMBL6288955

Cn1c(=O)c(Cc2ccc(C(=O)O)cc2)cc2nc(C#CCc3ccccc3)oc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.44
SLC22A8 Q8TCC7 1/20 0.44
TSHR P16473 1/20 0.37
HPGD P15428 2/20 0.35
KAT8 Q9H7Z6 1/20 0.35
TTR P02766 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
IP6K1 Q92551 1/20 0.34
IP6K3 Q96PC2 1/20 0.34
IP6K2 Q9UHH9 1/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC11 Q96DB2 2/20 0.34
HDAC8 Q9BY41 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
RXRA P19793 1/20 0.34
HDAC2 Q92769 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292735 0.84 MMP13 (0.35) MMP13SLC22A8RXFP1PDE3BPDE3A
SCHEMBL6289330 0.80 MMP13 (0.38) MMP13SLC22A8TSHRHPGDKAT8
SCHEMBL6288798 0.73 MMP13 (0.41) MMP13SLC22A8TSHRHPGDTTR
SCHEMBL6288761 0.73 PDE3B (0.40) MMP13SLC22A8RXFP1PDE3BPDE3A
SCHEMBL6292710 0.71 MMP13 (0.43) MMP13SLC22A8TSHRHPGDKAT8
SCHEMBL6292704 0.70 PDE3B (0.40) HPGDRXFP1PDE3BPDE3AKDM4E
SCHEMBL6289351 0.67 MMP13 (0.35) MMP13TSHRMEN1KMT2A
SCHEMBL6698262 0.67 MMP13 (0.57) MMP13SLC22A8TSHRMEN1KMT2A
SCHEMBL6703290 0.67 MMP13 (0.43) MMP13SLC22A8HDAC1HDAC8HDAC6
SCHEMBL6289326 0.67 MMP13 (0.43) MMP13SLC22A8HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 MMP13 9/4885SLC22A8 2735/4885TSHR 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.